APAndrej Pernat

Andrej Pernat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrej Pernat has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inappropriate Sinus Tachycardia in Athletes: Could Nutraceuticals Play a Role?

    by Antonio Scarà, Alessio Borrelli, Antonio Gianluca Robles, Sara Burazor, Lorenzo-Lupo Dei, Federico Zanin, Leonardo Pignalosa, Elena Cavarretta, Liuba Fusco, Andrej Pernat, et al.

    Introduction: Inappropriate sinus tachycardia (IST) is a syndrome characterized by unexpectedly fast and prolonged sinus rates at rest or with minimal physical activity. Epidemiologic characteristics are uncertain, but most patients are young and female. When IST occurs in athletes, its management (controlling symptoms and reducing heart rate) can present additional challenges. We designed an observational pilot study to investigate whether a food supplement can be useful in the treatment of IST when standard therapy is refused. Methods: We enrolled 50 consecutive recreational athletes affected by frequent recurrences of IST. Twelve-lead ECG and Holter ECG parameters were recorded at enrollment (T0) and after a 6-month treatment (T1) with the food supplement. Symptoms and quality of life were also evaluated through specific questionnaires. The study population was compared to a historical control group of 25 patients receiving ivabradine as treatment for the same clinical condition. Results: The resting ECG heart rate was 88.7 ± 12.4 bpm (T0) and 73.6 ± 6.6 bpm (T1) (p < 0.00001); Holter average heart rate was 88.4 ± 3.3 bpm and 74.9 ± 4.8 bpm (p < 0.0001). Holter ECG maximum heart rate was 147.1 ± 16.7 bpm and 139.2 ± 16.8 bpm (p = 0.06); Holter minimum heart rate was 49.9 ± 6.5 bpm and 50.5 ± 6.9 bpm (p = 0.33). Finally, the number of sustained episodes decreased from 3.3 ± 1.7 to 0.8 ± 0.8 (p < 0.00001). The following variations in ASTA scores were observed: ASTA symptom scale (range: 0–27) decreased from 14.9 ± 2.1 to 5.8 ± 1.4 (p < 0.00001), while ASTA HR QoL (range: 0–39) decreased from 24.1 ± 2.1 to 10.8 ± 2.3 (p < 0.00001). Conclusions: The findings of our pilot study suggest that this food supplement could play a beneficial role in managing symptoms and improving quality of life in recreational athletes affected by IST who refuse standard medical therapy. These clinical effects appear to correlate with significant improvements in resting ECG parameters and some Holter ECG parameters.

  • Improvement of Atrial and Ventricular Remodeling with Low Atrial Fibrillation Burden after Hybrid Ablation of Persistent Atrial Fibrillation

    by Janez Toplisek, Andrej Pernat, Nada Ruzic, Boris Robic, Matjaz Sinkovec, Marta Cvijic, Borut Gersak

    Background: An endoscopic transdiaphragmatic epicardial radiofrequency ablation procedure combined with percutaneous endocardial radiofrequency ablation—a hybrid procedure—is a potentially curative treatment option for patients with persistent atrial fibrillation (AF). Long‐term effects of arrhythmia elimination on atrial and ventricular remodeling are not completely understood. Therefore, the aim of our study was to quantify echocardiographic structural and functional changes of the left atrium (LA) and left ventricle (LV) following a hybrid procedure.Methods and Results: Thirty‐seven consecutive patients with symptomatic drug refractory persistent AF underwent a hybrid procedure to achieve complete pulmonary vein and LA posterior wall electrical isolation. AF burden was measured using an insertable electrocardiographic (ECG) monitor. Patients were divided into responders to ablation and nonresponders according to postoperative AF burden at 12‐month follow‐up (responder < 0.5% vs nonresponder ≥0.5%). Median AF burden was 0.32 (0.04–27.5)% for all patients. In responders (19/37 patients), significant echocardiographic reduction of LA volume index from 47 to 41 mL/m2 (P < 0.05) and improvement of LA function parameters (LA stiffness from 73.3 to 41.3 [P < 0.05], LA emptying fraction from 21% to 45% [P < 0.05], LA global longitudinal strain from 11.2% to 18.8% [P < 0.5]) was documented. In addition, LV systolic function significantly improved in comparison with nonresponders.Conclusion: Hybrid ablation of persistent AF achieved stable sinus rhythm in a significant proportion of patients, as evidenced by continuous ECG monitoring, resulting in important LA and LV reverse remodeling after 12 months.


  • Hemoglobin A1c is a better predictor of prognosis following the non-ST elevation acute coronary syndrome than fasting and admission glucose

    by Marko Kmet, Borut Rajer, Andrej Pernat

    Glucometabolic status is an important predictor of prognosis in patients with acute myocardial infarction. Both plasma glucose levels and glycosylated hemoglobin A1c (HbA1c) were implicated as predictors of prognosis. However, previous data yielded conflicting results. We evaluated the prognostic role of plasma glucose levels and HbA1c in patients with non-ST elevation acute coronary syndrome (NSTEACS). A total of 106 consecutive patients with NSTEACS (55 with unstable angina and 51 with non-ST elevation myocardial infarction) were included. The average age was 66.1 years; 61 % were male. HbA1c was measured at admission, along with other standard laboratory values. The follow-up period lasted for a year. The main combined outcome variable included death from cardiovascular causes and rehospitalization due to another acute coronary syndrome or due to heart failure. Combined end point occurred in 43 (41 %) patients. Mean HbA1c value was significantly higher in the group of patients who had complications (7.6 ± 2.6 vs. 5.8 ± 1.2, p HbA1c [odds ratio (OR): 1.6] and male sex (OR: 0.25) as the only independent predictors of major adverse cardiac events (MACE). A Kaplan–Meier analysis showed a 2.7 times higher risk of MACE in patients with HbA1c > 6.5 %. Results from our study indicate that the admission level of HbA1c, but not admission or fasting glucose, is a predictor of mortality and major adverse events in patients with NSTEACS. These results identify HbA1c to be an independent predictor also in patients with NSTEACS, and not only in those with ST elevation myocardial infarction as observed before our study. Glukosemetabolismus ist ein wichtiger Prädiktor für die Prognose bei Patienten mit akutem Herzinfarkt (AMI). Die Plasma Glucose-Konzentration sowie glykosyliertes Hämoglobin (HbA1c) waren Prädiktoren für die Prognose. Vorherige Daten brachten aber widersprüchliche Ergebnisse. Wir untersuchten die prognostische Rolle der Plasma Glucose-Konzentrationen und HbA1c bei Patienten mit akutem Koronarsyndrom ohne ST-Hebungen (NSTEACS). 106 Patienten mit NSTEACS (55 mit instabiler Angina und 51 mit Nicht-ST-Hebungsinfarkt) wurden im prospektiven Design inkludiert. Das durchschnittliche Alter war 66,1 Jahre, 61 % waren Männer. HbA1c wurde bei der Einlieferung gemessen, gemeinsam mit den anderen Standardlaborwerten. Die Nachbeobachtungszeit dauerte ein Jahr. Die Zielvariable schließt Tod durch kardiovaskulare Ursachen und Rehospitalisierung wegen eines anderen akuten Koronarsyndroms oder wegen der Herzinsuffizienz ein (Major Adverse Cardiac Events – MACE). Der kombinierte Endpunkt erschien bei 43 (41 %) Patienten. Der durchschnittliche HbA1c-Wert war deutlich höher bei der Gruppe der Patienten mit Störungen (7,6 ± 2,6 vs. 5,8 ± 1,2, p HbA1c (OR 1,6) und das männliche Geschlecht (OR 0,25) als unabhängige Prädiktoren des MACE. Die Kaplan-Meier-Analyse zeigte ein 2,7 mal höheres MACE-Risiko bei Patienten mit HbA1c > 6,5 %. Die Ergebnisse unserer Studie zeigen, dass nur HbA1c zum Zeitpunkt der klinischen Aufnahme und nicht die Nüchternglukose-Konzentration ein Prädiktor für die Mortalität und MACE bei Patienten mit NSTEACS ist. Diese Ergebnisse erweitern frühere Beobachtungen über den prognostischen Wert von HbA1c bei Patienten mit ST-Hebungsinfarkt auf die NSTEACS-Gruppe.


  • Open Access

    Feasibility of early hospital discharge directly from coronary care unit after primary angioplasty for uncomplicated acute myocardial infarction

    by Andrej Pernat, Mitja Lainscak, Aleksandra Mohar, Marko Noc

    Current European and American guidelines recommend early discharge for patients with uncomplicated acute myocardial infarction (AMI). However, this concept has not been widely accepted, and experience with direct discharge from the coronary care unit is limited. We aimed to investigate safety and cost effectiveness of early discharge directly from coronary care unit following successful percutaneous coronary angioplasty (PTCA) in patients with uncomplicated AMI. We included consecutive thirty-one patients with uncomplicated AMI and successful PTCA admitted to coronary care unit of a university hospital. Uncomplicated course was defined as absence of reinfarction, ischemia, VF/VT, repeated PTCA, and heart failure within first 72 hours. Incidence of death, reinfarction, VF/VT, need for revascularisation, and hospitalisation due to heart failure at 1, 6, and 12 months was compared with 56 randomly selected AMI patients with successful PTCA but longer hospitalisation. Average hospital stay was 4 days in early and 6.7 days in control group (p<0.05). Control group had more extensive coronary disease (54% two or more vessels vs. 28% in early discharge, p<0,05). During follow up, none of the early discharged patients died, the only observed event was repeat PTCA due to angina pectoris. In the control group, mortality at 12 months was 3.5% (p<0.05). Cumulative 12 month event free survival was 96% in early discharge group and 87% in control group, but difference was not significant (p=0.15, Cox-Mantel test). Cost reduction of early discharge amounted to 1100 Euro per patient. In conclusions, our study confirmed that for a selected population of patients with AMI, successful PTCA, and uncomplicated clinical course during first 72 hours, discharge as early as three days following the admission is safe.

  • Two cases of complications of the thrombolysis of right heart free-floating thrombi with pulmonary embolism: Important role of echocardiographically based management

    by A. Pernat, M. Logar, S.K. Zorman

    We present two cases where successful thrombolysis of right heart thrombi and pulmonary embolism was accompanied by serious adverse events. In patient 1 with massive pulmonary thromboembolism, transesophageal ultrasound revealed large right atrial thrombus entrapped in a patent foramen ovale. Initial treatment with heparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage. In patient 2, thrombolysis caused mobilisation of thrombotic mass as evidenced by disappearance of thrombus on ultrasound. Massive pulmonary thromboembolism resulted in circulatory collapse. Short cardiopulmonary resuscitation restored spontaneous circulation and the patient recovered completely.